2seventy bio, Inc.

NasdaqGS:TSVT Stok Raporu

Piyasa değeri: US$163.0m

2seventy bio Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

2seventy bio yıllık ortalama 12.3% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.1% annual. Gelirler azalıyor .

Anahtar bilgiler

12.3%

Kazanç büyüme oranı

31.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı-6.2%
Özkaynak getirisi-41.5%
Net Marj-207.3%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

Nov 15
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Oct 03
There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Jul 04
2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

May 11
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 03

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07
These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06
2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17
Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13
2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05
Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21
Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19
2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

Oct 04
We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

Sep 08

2seventy bio Prospects

Aug 23

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12
Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Gelir ve Gider Dağılımı

2seventy bio nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:TSVT Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 2446-95520
30 Jun 2444-156520
31 Mar 2471-223610
31 Dec 23100-218690
30 Sep 23146-184720
30 Jun 23147-180790
31 Mar 23125-215760
31 Dec 2291-254790
30 Sep 2251-292850
30 Jun 2257-284890
31 Mar 2251-291930
31 Dec 2155-292940
30 Sep 2148-308910
30 Jun 2148-320900
31 Mar 21150-222920
31 Dec 20248-120910
31 Dec 1944-321820
31 Dec 1855-200540

Kaliteli Kazançlar: TSVT şu anda kârlı değil.

Büyüyen Kar Marjı: TSVT şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: TSVT kârlı değildir, ancak son 5 yılda zararlarını yılda 12.3% oranında azaltmıştır.

Büyüme Hızlandırma: TSVT 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: TSVT kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: TSVT hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -41.45% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin